BACKGROUND:Adults with acquired immune deficiency syndrome and persistent diarrhoea in Zambia have intestinal infection, predominantly protozoa. AIM: To search for treatment which can be offered with minimal investigation, we carried out a double-blind, randomized-controlled trial of nitazoxanide (a drug with a range of activity against parasites and bacteria). METHODS:Patients with diarrhoea of 1 month duration or longer were randomized to receive nitazoxanide (1000 mg twice daily) or placebo for 2 weeks. End-points were clinical response, parasitological clearance and mortality. RESULTS:Two hundred and seven adults were randomized; 42 died during the study. The primary assessment of efficacy was made after 17 days. Clinical response was observed in 56 (75%) of 75 patients receiving nitazoxanide and 45 (58%) of 77 patients receiving placebo (P = 0.03). The rate of improvement was markedly higher in patients with CD4 counts under 50 cells/microL receiving nitazoxanide (P = 0.007). The benefit was largely restricted to the period when the drug was being administered. No difference was seen in parasitological clearance between the two groups. Mortality was 19% by 4 weeks of follow-up and did not differ with treatment allocation. CONCLUSIONS:Nitazoxanide given orally for 14 days was associated with clinical improvement in Zambian acquired immune deficiency syndrome patients with diarrhoea, especially those with very low CD4 counts.
RCT Entities:
BACKGROUND: Adults with acquired immune deficiency syndrome and persistent diarrhoea in Zambia have intestinal infection, predominantly protozoa. AIM: To search for treatment which can be offered with minimal investigation, we carried out a double-blind, randomized-controlled trial of nitazoxanide (a drug with a range of activity against parasites and bacteria). METHODS:Patients with diarrhoea of 1 month duration or longer were randomized to receive nitazoxanide (1000 mg twice daily) or placebo for 2 weeks. End-points were clinical response, parasitological clearance and mortality. RESULTS: Two hundred and seven adults were randomized; 42 died during the study. The primary assessment of efficacy was made after 17 days. Clinical response was observed in 56 (75%) of 75 patients receiving nitazoxanide and 45 (58%) of 77 patients receiving placebo (P = 0.03). The rate of improvement was markedly higher in patients with CD4 counts under 50 cells/microL receiving nitazoxanide (P = 0.007). The benefit was largely restricted to the period when the drug was being administered. No difference was seen in parasitological clearance between the two groups. Mortality was 19% by 4 weeks of follow-up and did not differ with treatment allocation. CONCLUSIONS:Nitazoxanide given orally for 14 days was associated with clinical improvement in Zambian acquired immune deficiency syndromepatients with diarrhoea, especially those with very low CD4 counts.
Authors: Lourrany B Costa; Eric A JohnBull; Jordan T Reeves; Jesus Emmanuel Sevilleja; Rosemayre S Freire; Paul S Hoffman; Aldo A M Lima; Reinaldo B Oriá; James K Roche; Richard L Guerrant; Cirle Alcantara Warren Journal: J Parasitol Date: 2011-06-28 Impact factor: 1.276
Authors: Paul S Hoffman; Gary Sisson; Matthew A Croxen; Kevin Welch; W Dean Harman; Nunilo Cremades; Michael G Morash Journal: Antimicrob Agents Chemother Date: 2006-12-11 Impact factor: 5.191
Authors: Eliah R Shamir; Michelle Warthan; Sareena P Brown; James P Nataro; Richard L Guerrant; Paul S Hoffman Journal: Antimicrob Agents Chemother Date: 2010-01-19 Impact factor: 5.191
Authors: Momar Ndao; Milli Nath-Chowdhury; Mohammed Sajid; Victoria Marcus; Susan T Mashiyama; Judy Sakanari; Eric Chow; Zachary Mackey; Kirkwood M Land; Matthew P Jacobson; Chakrapani Kalyanaraman; James H McKerrow; Michael J Arrowood; Conor R Caffrey Journal: Antimicrob Agents Chemother Date: 2013-09-23 Impact factor: 5.191
Authors: Py Iroh Tam; S L M Arnold; L K Barrett; C R Chen; T M Conrad; E Douglas; M A Gordon; D Hebert; M Henrion; D Hermann; B Hollingsworth; E Houpt; K C Jere; R Lindblad; M S Love; L Makhaza; C W McNamara; W Nedi; J Nyirenda; D J Operario; J Phulusa; G V Quinnan; L A Sawyer; H Thole; N Toto; A Winter; W C Van Voorhis Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079